NCT02063386

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

A Phase I, Single-centre, Open-label Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of a Single Oral Dose of 14C-labelled AZD1722 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Ardelyx · Industry
• Sex: Male
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	AZD1722	Single oral dose 15 mg of \[14C\]AZD1722

Timeline

• Start date: 2014-04-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2014-02-14
• Last updated: 2015-09-22

Locations

1 site across 1 country: United Kingdom